Brivanib Metastatic Renal Cell Carcinoma

Inclusion Criteria: * Male and female adults with metastatic renal cell carcinoma * Patients will have tumors that bear a clear cell component that comprises greater than or equal to 50% of the tumor. * Disease must be measurable in accord with RECIST 1.1 guidelines. * Patients who have developed progressive disease or intolerance on treatment with sorafenib, sunitinib, bevacizumab, or pazopanib over a 60 day period who have not discontinued this therapy more than 100 days prior to study enrollment. Progressive disease per RECIST 1.1 guidelines will be preferred * Therapy with up to three prior systemic regimens will be allowed. * Patients may have been treated with any of the following: sorafenib, sunitinib, bevacizumab, pazopanib, temsirolimus, everolimus, interferon alpha, interleuken-2. * Treatment with up to one prior regimen that included cytotoxic chemotherapy will be allowed. * Patients may have been treated with more than 1 antiangiogenic therapy (e.g., patients may have been treated with both sorafenib and sunitinib or sunitinib and bevacizumab, or sequential combinations that include pazopanib). * Life expectancy of at least 3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Tumor tissue must be available for correlative studies. * Patients must consent to allow the acquisition of formalin-fixed paraffin-embedded (FFPE) material (block or unstained slides) by study personnel for performance of correlative tissue studies. Exclusion Criteria: * Known brain metastases * Prior therapy with brivanib, or anti-FGFR (fibroblast growth factor receptor) therapy. * History of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism. * Gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE version 4.0 Grade greater than 3 within 30 days prior to study entry. * Uncontrolled or significant cardiovascular disease. * QTc greater than 450 msec on two consecutive ECGs (Baseline ECG should be repeated if QTc is found to be greater than 450 msec.). * Active infection, less than 7 days after completing systemic antibiotic therapy. * History of non-healing wounds or ulcers or bone fractures within 3 months of fracture. * Major surgical procedure, open biopsy, or significant traumatic injury less than 3 weeks prior to study enrollment or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration)within 1 week prior to study enrollment. * Cytotoxic chemotherapy within 3 weeks, bevacizumab within 2 months, or radiation therapy within 2 weeks, other targeted therapies (e.g., sorafenib, sunitinib, temsirolimus, everolimus)within 2 days. * Inability to swallow tablets or untreated malabsorption syndrome. * Pre-existing thyroid abnormality with thyroid function that cannot be controlled with medication. * History of HIV * Patients with centrally cavitating lung lesions. * Patients requiring therapeutic anticoagulation with warfarin at baseline. However, prophylactic therapy with a low molecular weight heparin at baseline is acceptable.